[CTLT] Catalent, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 2.96 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 26.9 Change: 0.56 (2.13%)
Ext. hours: Change: 0 (0%)

chart CTLT

Refresh chart

Strongest Trends Summary For CTLT

CTLT is in the medium-term up 11% above S&P in 2 months and up 43% in 5 months and up 48% above S&P in 1 year. In the long-term up 121% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment?s oral dose forms include soft gel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development & Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scient

Fundamental Ratios
Shares Outstanding124.71 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -14.05% Sales Growth - Q/Q-2.02% P/E
P/E To EPS Growth P/S1.61 P/BV6.33 Price/Cash Per Share
Price/Free Cash Flow53.01 ROA2.88% ROE18.13% ROI3.43%
Current Ratio1.79 Quick Ratio1.4 Long Term Debt/Equity6.45 Debt Ratio0.77
Gross Margin33.9% Operating Margin14.77% Net Profit Margin4.66% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities209 M Cash From Investing Activities-240.3 M Cash From Operating Activities94.7 M Gross Profit152.2 M
Net Profit31.5 M Operating Profit65.8 M Total Assets2.97 B Total Current Assets653.1 M
Total Current Liabilities365.4 M Total Debt1.88 B Total Liabilities2.51 B Total Revenue446.6 M
Technical Data
High 52 week58.05 Low 52 week29.84 Last close57.19 Last change0%
RSI58.49 Average true range1.67 Beta1.08 Volume419.58 K
Simple moving average 20 days2.98% Simple moving average 50 days7.76% Simple moving average 200 days32.85%
Performance Data
Performance Week3.81% Performance Month5.4% Performance Quart27.74% Performance Half44.02%
Performance Year41.88% Performance Year-to-date83.42% Volatility daily1.7% Volatility weekly3.79%
Volatility monthly7.77% Volatility yearly26.92% Relative Volume271.85% Average Volume738.2 K
New High New Low


2019-09-13 08:34:14 | Does Catalent NYSE:CTLT Have A Healthy Balance Sheet?

2019-09-06 09:40:01 | JAZZ vs. CTLT: Which Stock Is the Better Value Option?

2019-09-04 09:15:01 | Lannett LCI Hits 52-Week High, Can the Run Continue?

2019-09-02 09:00:01 | Catalent CTLT Upgraded to Buy: Here's Why

2019-08-30 08:48:44 | Edited Transcript of CTLT earnings conference call or presentation 27-Aug-19 12:15pm GMT

2019-08-28 14:42:17 | Catalent Analyst Cites Valuation Concerns In Downgrade

2019-08-27 16:20:24 | This Surging Medical Stock Beats Views, But Shares Take A Breather

2019-08-27 12:23:29 | Catalent Inc CTLT Q4 2019 Earnings Call Transcript

2019-08-27 08:55:12 | Catalent CTLT Surpasses Q4 Earnings and Revenue Estimates

2019-08-27 07:48:02 | Catalent Reports Q4 Earnings Beat

2019-08-27 07:30:00 | Catalent, Inc. Reports Fourth Quarter Fiscal 2019 Results

2019-08-26 14:35:13 | Catalent's Q4 Earnings Outlook

2019-08-26 13:13:03 | What Are Analysts Saying About Catalent, Inc.'s NYSE:CTLT Growth?

2019-08-21 06:11:09 | Read This Before Judging Catalent, Inc.'s NYSE:CTLT ROE

2019-08-20 10:30:02 | Earnings Preview: Catalent CTLT Q4 Earnings Expected to Decline

2019-08-19 10:10:02 | Medtronic MDT to Post Q1 Earnings: Will RTG Aid the Stock?

2019-08-16 10:49:02 | Medtronic MDT to Report Q1 Earnings: What's in Store?

2019-08-09 10:42:02 | Tilray TLRY to Report Q2 Earnings: What's in the Cards?

2019-08-07 18:32:20 | Novavax looks to next flu vaccine trial following sale of manufacturing business

2019-07-31 10:10:02 | Why Catalent CTLT is Poised to Beat Earnings Estimates Again

2019-07-24 14:45:36 | 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar

2019-07-17 16:15:00 | Catalent, Inc. Announces Fourth Quarter Fiscal Year 2019 Earnings Conference Webcast

2019-07-15 09:30:01 | CTLT vs. ZTS: Which Stock Is the Better Value Option?

2019-07-12 13:42:00 | Here's Why Catalent Stock Soared 73.9% in the First Half of 2019

2019-07-09 07:00:00 | Catalent Extends Global Commercial Spray Drying Capabilities in Europe

2019-06-27 07:00:00 | Novavax selling manufacturing business amid good news for flu vaccine

2019-06-24 14:56:00 | Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2027

2019-06-24 14:03:08 | Catalent Pharma Solutions, Inc. -- Moody's assigns B3 rating to Catalent's notes offering

2019-06-24 07:24:00 | Catalent Announces Launch of Private Offering of $500 Million of Senior Unsecured Notes Due 2027

2019-06-23 16:10:53 | Did Hedge Funds Drop The Ball On Catalent Inc CTLT ?

2019-06-19 09:00:01 | Catalent CTLT Upgraded to Buy: What Does It Mean for the Stock?

2019-06-19 06:59:00 | Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

2019-06-10 08:06:38 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-05-30 16:15:00 | Catalent, Inc. to Present at the Jefferies Healthcare Conference

2019-05-30 08:04:59 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-05-28 08:05:07 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-05-21 08:52:12 | Catalent Acquires Gene Therapy Leader Paragon Bioservices

2019-05-20 08:30:00 | Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

2019-05-09 14:20:11 | Catalent Pharma Solutions, Inc. -- Moody's downgrades Catalent's senior secured rating to Ba3, affirms B1 CFR rating; the outlook remains stable

2019-05-08 08:31:01 | Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT

2019-05-07 14:23:34 | Catalent Inc CTLT Q3 2019 Earnings Call Transcript

2019-05-07 08:55:12 | Catalent CTLT Surpasses Q3 Earnings Estimates

2019-05-07 08:03:34 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-05-07 07:45:36 | Catalent: Fiscal 3Q Earnings Snapshot

2019-05-07 07:30:00 | Catalent, Inc. Reports Third Quarter Fiscal 2019 Results

2019-04-30 10:32:02 | Catalent CTLT Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2019-04-24 10:52:31 | Did Hedge Funds Drop The Ball On Catalent Inc CTLT ?

2019-04-17 16:05:16 | Catalent Pharma Solutions, Inc. -- Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.

2019-04-17 11:37:08 | Catalent Pharma Solutions, Inc. -- Moody's: Catalent's acquisition of Paragon will increase leverage, a credit negative

2019-04-15 15:33:27 | Catalent seeks slice of gene therapy market with Paragon buy